Kieron Dunleavy

Has grant

Director

Georgetown University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Administration of HIV-specific T cells to HIV+Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST’.

Open Date: 2021-01-01

Close Date:

Grant: Close

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Open Date:

Close Date:

Grant: Close

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Open Date:

Close Date:

Grant: Close

A Phase Ib Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Open Date:

Close Date:

Grant: Close

A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Open Date:

Close Date:

Articles (19)

Year:

2025

Year:

2025

This review aims to provide an overview of the latest developments in the classification and molecular understanding of aggressive B‐cell lymphomas, specifically focusing on diffuse large B‐cell lymphoma (DLBCL) and high‐grade B‐cell lymphoma (HGBL). Advances in molecular techniques have led to novel ways to classify these lymphomas based on clinical, histological, transcriptional, and genetic properties. While these methods have predominantly focused on the malignant compartment, recent studies emphasize the value of profiling the tumour microenvironment for a more comprehensive disease classification. Additionally, the integration of liquid biopsies represents a promising advancement, offering less invasive and dynamic insights into tumour characteristics and treatment response. Although molecular profiles are not yet routinely used to guide therapy, emerging data highlight their potential to predict responses to novel treatments. It is our belief that integrating molecular profiling and liquid biopsies into clinical practice and research now will pave the way for more personalized and effective therapies in the future.

Year:

2025

Introduction: Chemotherapy-free, bispecific antibody (BsAb)-containing therapies have the potential to challenge the role of standard chemoimmunotherapy as frontline treatment of patients (pts) with follicular lymphoma (FL) in need of systemic therapy. In the multicenter phase 2 MITHIC-FL1 trial subcutaneous (SC) mosunetuzumab produced high complete response (CR) rates with manageable adverse events (AE) (Falchi et al. ASH 2024). Zanubrutinib is a second-generation BTK inhibitor with direct anti-FL activity and the potential ability to correct defective T-cell function, which may synergistically enhance BsAb-mediated tumor-killing. Here, we present the first results of MITHIC-FL2, a multicenter phase 2 trial of mosunetuzumab with zanubrutinib in patients with previously untreated FL. Methods: Key eligibility criteria included: Age ≥18 y, ECOG PS 0-2, biopsy-proven CD20+, grade 1-3A FL, stage 2-4, need for therapy per GELF criteria. SC mosunetuzumab was administered on a step-up dosing schedule in cycle (C)1 (5 mg on day [D]1, 45 mg on D8 and 45 mg on D15), then at 45 mg on D1 every 21 days for up to 8 Cs (if CR was achieved) or 17 Cs (if partial response [PR] was achieved). Zanubrutinib was administered orally at the dose of 320 mg daily or 160 mg twice daily starting on C1D-7 and continued daily for 12 months. Premedication with single-dose dexamethasone, diphenhydramine, and acetaminophen was mandatory before each mosun dose in C1 (and C2 if cytokine release syndrome (CRS) occurred in C1), optional thereafter. Treatment was administered on an outpatient basis. The primary endpoint was complete response (CR) rate at the end of study therapy. Response was assessed following the Lugano 2014 criteria, complemented by the LYRIC criteria. Cytokine release syndrome (CRS) and neurological adverse events (AE) were graded according to the 2019 ASTCT criteria. Results: Between August 2024 and July 2025, 47 pts were enrolled and 45 pts received ≥1 dose of study drug and are safety evaluable. The median age was 59 years (range 33-79), 40% of pts had bulky disease (≥7 cm), 20% had grade 3A FL, and 18% had a FLIPI score ≥3. The median baseline SUVmax was 11.8 (range 5.6-33.6). As of the July 1, 2025 cutoff date, 40 pts remained on treatment; 2 pts discontinued early due to biopsy-confirmed progression (PD), 1 due to stable disease (SD) per physician discretion, 1 due to AE, and 1 discontinued on C1D8 due to later finding of diffuse large B-cell lymphoma on pre-treatment bone marrow biopsy. At a median follow up of 3.8 months, pts have received a median of 6 mosunetuzumab cycles (range 1-10) and 4.2 months of zanubrutinib treatment (range 0.1-10.5). Out of 232 mosunetuzumab patient-cycles administered, 10 (4%) were delayed due to AEs by a median of 7 days (range 4-21). Five pts experienced zanubrutinib dose interruptions due to AE, lasting ≤7 days in 3 of them. Among 45 safety-evaluable pts, the most common (≥20%) treatment-emergent AE were injection site reactions (62%), CRS (56%), dry skin (53%), infections (29%), fatigue (27%), and skin rash (27%); all of these events were G1-2. Bruising/bleeding occurred in 15% of pts, all G1. CRS occurred mostly after C1D1 and was either G1 (21/25 pts, 84%) or G2 (4/25 pts 16%). G≥3 AEs included neutropenia (2 pts, 4%), anemia (1 pt, 2%), and LFT elevation (1 pt, 2%). One pt had G3 vasovagal syncope and another had G3 acute kidney injury due to ureteral obstruction caused by PD. One pt developed G5 EBV-associated hemophagocytic lymphohistiocytosis during Cycle 1. This pt had negative EBER staining on baseline biopsy and did not have detectable EBV viral load at baseline. No neurotoxicity, clinical TLS, or atrial fibrillation were seen. Thus far, 27 pts are evaluable for response. The best overall response rate is 85% (23/27) and the metabolic CR rate is 74% (20/27); 2 pt had SD, and 2 pts had PD. At a median follow-up for response-evaluable pts of 5.1 months, no pt with an objective response has progre

Year:

2025

Burkitt lymphoma (BL) is a rare, aggressive B-cell lymphoma that is characterized by rapid tumor proliferation and frequent extra-nodal involvement. While prompt diagnosis and initiation of highly intensive chemotherapy results in cure rates over 90% in children and adolescents, outcomes in adults are more modest, as comorbidities and advancing age may compromise treatment tolerability. In recent years, intermediate-intensity regimens have been developed for BL. These are highly effective in patients of all ages and associated with significantly less treatment-related toxicity compared to traditional high-dose chemotherapy. This was demonstrated in a recent randomized study of dose-intensive R-CODOX-M/R-IVAC compared to the reduced-intensity DA-EPOCH-R regimen, which was associated with equivalent outcomes but with significantly fewer side effects. Regardless of the chemotherapy platform, CNS involvement at baseline predicts a significantly inferior outcome, and the development of an optimal approach for these patients is an area of unmet need in BL therapeutics. Patients with relapsed or refractory disease following frontline therapy have very short survival times, as currently available salvage options are largely ineffective. In this regard, novel agents such as anti-CD19 CAR-T cells and bi-specific antibodies are under development in BL. It is hoped that progress in novel drug development, alongside improved understanding of BL biology, to further elucidate its genetic and epigenetic vulnerabilities, will lead to improved outcomes for patients in the future.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more. PURPOSE To guide the vaccination of adults with solid tumors or hematologic malignancies. METHODS A systematic literature review identified systematic reviews, randomized controlled trials (RCTs), and nonrandomized studies on the efficacy and safety of vaccines used by adults with cancer or their household contacts. This review builds on a 2013 guideline by the Infectious Disease Society of America. PubMed and the Cochrane Library were searched from January 1, 2013, to February 16, 2023. ASCO convened an Expert Panel to review the evidence and formulate recommendations. RESULTS A total of 102 publications were included in the systematic review: 24 systematic reviews, 14 RCTs, and 64 nonrandomized studies. The largest body of evidence addressed COVID-19 vaccines. RECOMMENDATIONS The goal of vaccination is to limit the severity of infection and prevent infection where feasible. Optimizing vaccination status should be considered a key element in the care of patients with cancer. This approach includes the documentation of vaccination status at the time of the first patient visit; timely provision of recommended vaccines; and appropriate revaccination after hematopoietic stem-cell transplantation, chimeric antigen receptor T-cell therapy, or B-cell–depleting therapy. Active interaction and coordination among healthcare providers, including primary care practitioners, pharmacists, and nursing team members, are needed. Vaccination of household contacts will enhance protection for patients with cancer. Some vaccination and revaccination plans for patients with cancer may be affected by the underlying immune status and the anticancer therapy received. As a result, vaccine strategies may differ from the vaccine recommendations for the general healthy adult population vaccine. Additional information is available at www.asco.org/supportive-care-guidelines .

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (23)

Kikkeri N Naresh

Section Head of Pathology & Professor

University of Washington

UNITED STATES
View details

Javeed Iqbal

Professor, Odeth E. Wall Centennial Professor of Oncology

University of Nebraska Medical Center

UNITED STATES
View details

Per Ljungman

Karolinska University Hospital

SWEDEN
View details

Chris Bacon

Clinical Senior Lecturer/Consultant

Newcastle University

UNITED KINGDOM
View details

Seiichi Kato

Professor

Saga University

JAPAN
View details

Lorenzo Leoncini

Docenti di ruolo di Ia fascia

University of Siena

ITALY
View details

Brian Walker

Professor

University of Miami

UNITED STATES
View details

Lacey Williams

Assistant Professor

University of North Carolina

UNITED STATES
View details

Michael Cook

Assistant Professor of Clinical Medicine

Hospital of the University of Pennsylvania

UNITED STATES
View details

Pedro Farinha

Clinical Professor

The University of British Columbia

CANADA
View details

Catalina Amador

Professor of Pathology

University of Miami Health System

UNITED STATES
View details

John Choi

The University of Alabama

UNITED STATES
View details

Robert Hal Scofield

Member

Oklahoma Medical Research Foundation

UNITED STATES
View details

Rahul Lakhotia

National Institutes of Health

UNITED STATES
View details

Reuben M. Tooze

Professor

University of Leeds

UNITED KINGDOM
View details

Sarah E. Coupland

Personal Chair

University of Liverpool

UNITED KINGDOM
View details

Edus Warren

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Davide Rossi

Associate Professor of Medicine

Università della Svizzera Italiana (USI)

SWITZERLAND
View details

Vaskar Saha

The University of Manchester

UNITED KINGDOM
View details

Bjoern Chapuy

Professoor

Charité - Universitätsmedizin Berlin

GERMANY
View details

Ajay Gopal

University of Washington

UNITED STATES
View details

Kim G. Hankey

Associate Professor

University of Maryland

UNITED STATES
View details

Alaa Ali

Georgetown University

UNITED STATES
View details